Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Non-Hodgkin 6Lymphoma, B-Cell 5Recurrence 4Burkitt Lymphoma 4Neoplasm, Residual 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia 3Multiple Myeloma 2Lymphoma, Mantle-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Glioma 2Glioblastoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Stomach Neoplasms 1Solid Tumors 1Simpson-Golabi-Behmel syndrome 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Platinum-Resistant Ovarian Carcinoma 1Pancreatic Neoplasms 1

Interventions

Rituximab 63Cyclophosphamide 57fludarabine phosphate 40fludarabine 37ibrutinib 28Lenalidomide 26Bendamustine Hydrochloride 26Filgrastim 20venetoclax 19obinutuzumab 17Bortezomib 17Peripheral Blood Stem Cell Transplantation 15Etoposide 12Biopsy 12Tacrolimus 11Specimen Handling 11Melphalan 11Interleukin-2 10tanespimycin 9Radiotherapy 9Cytarabine 9aldesleukin 8Whole-Body Irradiation 8Magnetic Resonance Spectroscopy 8idelalisib 7Vorinostat 7Paclitaxel 7Mycophenolic Acid 7Ipilimumab 7Cyclosporine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Lymphocytic, Chronic, B-Cell × Immunotherapy, Adoptive × Clear all
NCT04545762 2026-01-14

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco

Phase 1 Recruiting
36 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04007029 2025-09-05

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
24 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡